China Pharma (CPHI) 10-Q 14 Aug 24 2024 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2024	Aug. 12, 2024
Document Information Line Items
Entity Registrant Name	CHINA PHARMA HOLDINGS, INC.
Trading Symbol	CPHI
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		17,162,771
Amendment Flag	false
Entity Central Index Key	0001106644
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Jun. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-34471
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	75-1564807
Entity Address, Address Line One	Second Floor, No. 17, Jinpan Road
Entity Address, Address Line Two	Haikou
Entity Address, City or Town	Hainan Province
Entity Address, Country	CN
Entity Address, Postal Zip Code	570216
City Area Code	+86
Local Phone Number	898-6681-1730
Title of 12(b) Security	Common Stock
Security Exchange Name	NYSE
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 739,337	$ 1,423,838
Banker’s acceptances	15,435	65,915
Trade accounts receivable, less allowance for doubtful accounts of $13,706,077 and $13,786,074, respectively	254,850	504,448
Other receivables, less allowance for doubtful accounts of $27,929 and $27,017, respectively	28,660	157,944
Advances to suppliers	161	2,013
Inventories	2,818,925	3,732,517
Prepaid expenses	115,610	110,258
Total Current Assets	3,972,978	5,996,933
Property, plant and equipment, net	5,817,379	7,100,425
Right-of-use assets	77,259	116,610
Intangible assets, net	4,393,617	3,255,232
TOTAL ASSETS	14,261,233	16,469,200
Current Liabilities:
Trade accounts payable	141,036	966,420
Accrued expenses	208,831	298,829
Other payables	1,606,991	2,282,692
Advances from customers	101,056	90,507
Lease liabilities	78,628	77,727
Current portion of lines of credit	1,024,303	1,030,680
Convertible, redeemable note payable, net of issue discount	410,415	940,000
Total Current Liabilities	4,712,035	6,820,664
Non-current Liabilities:
Lines of credit, net of current portion	1,403,154	1,411,891
Deferred tax liability	737,522	742,114
Lease liabilities		39,910
Total Liabilities	6,852,711	9,014,579
Commitments and Contingencies (Note 14)
Stockholders’ Equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.001 par value; 500,000,000 shares authorized; 17,162,771 shares and 10,625,788 shares issued and outstanding, respectively	17,162	10,625
Additional paid-in capital	37,690,719	35,282,256
Accumulated deficit	(41,684,336)	(39,290,314)
Accumulated other comprehensive income	11,384,977	11,452,054
Total Stockholders’ Equity	7,408,522	7,454,621
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	14,261,233	16,469,200
Related Party
Current Liabilities:
Borrowings from related parties	$ 1,140,775	$ 1,133,809

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Trade accounts receivable, less allowance for doubtful accounts (in Dollars)	$ 13,706,077	$ 13,786,074
Other receivables, allowance for doubtful accounts (in Dollars)	$ 27,929	$ 27,017
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	17,162,771	10,625,788
Common stock, shares outstanding	17,162,771	10,625,788

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Revenue	$ 924,943	$ 1,097,862	$ 2,294,782	$ 3,058,152
Cost of revenue	1,940,329	1,244,523	3,600,192	3,026,889
Gross (loss) profit	(1,015,386)	(146,661)	(1,305,410)	31,263
Operating expenses:
Selling expenses	111,455	169,820	219,642	314,252
General and administrative expenses	91,870	112,033	580,326	530,032
Research and development expenses	164,334	23,747	195,785	46,755
Bad debt expense (reversal of allowance for doubtful accounts	8,476	4,047	6,410	(5,989)
Total operating expenses	376,135	309,647	1,002,163	885,050
Loss from operations	(1,391,521)	(456,308)	(2,307,573)	(853,787)
Other income (expense):
Interest income	1,531	942	3,846	1,890
Interest expense	(48,140)	(137,663)	(90,295)	(217,108)
Net other expense	(46,609)	(136,721)	(86,449)	(215,218)
Loss before income taxes	(1,438,130)	(593,029)	(2,394,022)	(1,069,005)
Income tax expense
Net loss	(1,438,130)	(593,029)	(2,394,022)	(1,069,005)
Other comprehensive loss - foreign currency translation adjustment	(45,502)	(523,687)	(67,077)	(318,365)
Comprehensive loss	$ (1,483,632)	$ (1,116,716)	$ (2,461,099)	$ (1,387,370)
Loss per share:
Basic (in Dollars per share)	$ (0.09)	$ (0.35)	$ (0.16)	$ (0.65)
Weighted average shares outstanding (in Shares)	16,124,241	1,689,985	14,727,410	1,653,076

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Diluted	$ (0.09)	$ (0.35)	$ (0.16)	$ (0.65)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Total
Balance at Dec. 31, 2022	$ 1,498	$ 28,926,931	$ (36,211,496)	$ 11,573,065	$ 4,289,998
Balance (in Shares) at Dec. 31, 2022	1,498,179
Conversions of Note Payable to common stock	$ 595	799,405			650,000
Conversions of Note Payable to common stock (in Shares)	191,806
Net loss for the period			(475,976)		(475,976)
Foreign currency translation adjustment				205,322	205,322
Balance at Mar. 31, 2023	$ 1,690	29,576,739	(36,687,472)	11,778,387	4,669,344
Balance (in Shares) at Mar. 31, 2023	1,689,985
Balance at Dec. 31, 2022	$ 1,498	28,926,931	(36,211,496)	11,573,065	4,289,998
Balance (in Shares) at Dec. 31, 2022	1,498,179
Net loss for the period					(1,069,005)
Balance at Jun. 30, 2023	$ 2,285	30,376,144	(36,280,501)	11,254,700	4,352,628
Balance (in Shares) at Jun. 30, 2023	2,284,927
Balance at Mar. 31, 2023	$ 1,690	29,576,739	(36,687,472)	11,778,387	4,669,344
Balance (in Shares) at Mar. 31, 2023	1,689,985
Conversions of Note Payable to common stock	$ 595	799,405			800,000
Conversions of Note Payable to common stock (in Shares)	594,941
Net loss for the period			(593,029)		(593,029)
Foreign currency translation adjustment				(45,502)	(45,502)
Balance at Jun. 30, 2023	$ 2,285	30,376,144	(36,280,501)	11,254,700	4,352,628
Balance (in Shares) at Jun. 30, 2023	2,284,927
Balance at Dec. 31, 2023	$ 10,625	35,282,256	(39,290,314)	11,452,054	7,454,621
Balance (in Shares) at Dec. 31, 2023	10,625,788
Conversions of Note Payable to common stock	$ 1,191	448,809			450,000
Conversions of Note Payable to common stock (in Shares)	1,191,077
Issuance of common stock for intangible assets	$ 3,000	1,362,000			1,365,000
Issuance of common stock for intangible assets (in Shares)	3,000,000
Net loss for the period			(955,892)		(955,892)
Foreign currency translation adjustment				(21,575)	(21,575)
Balance at Mar. 31, 2024	$ 14,816	37,093,065	(40,246,206)	11,430,479	8,292,154
Balance (in Shares) at Mar. 31, 2024	14,816,865
Balance at Dec. 31, 2023	$ 10,625	35,282,256	(39,290,314)	11,452,054	7,454,621
Balance (in Shares) at Dec. 31, 2023	10,625,788
Net loss for the period					(2,394,022)
Balance at Jun. 30, 2024	$ 17,162	37,690,719	(41,684,336)	11,384,977	7,408,522
Balance (in Shares) at Jun. 30, 2024	17,162,771
Balance at Mar. 31, 2024	$ 14,816	37,093,065	(40,246,206)	11,430,479	8,292,154
Balance (in Shares) at Mar. 31, 2024	14,816,865
Conversions of Note Payable to common stock	$ 2,346	597,654			600,000
Conversions of Note Payable to common stock (in Shares)	2,345,906
Net loss for the period			(1,438,130)		(1,438,130)
Foreign currency translation adjustment				(45,502)	(45,502)
Balance at Jun. 30, 2024	$ 17,162	$ 37,690,719	$ (41,684,336)	$ 11,384,977	$ 7,408,522
Balance (in Shares) at Jun. 30, 2024	17,162,771

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash Flows from Operating Activities:
Net loss	$ (2,394,022)	$ (1,069,005)
Depreciation and amortization	1,473,050	1,374,724
Bad debt expense (reversal of allowance for doubtful accounts)	6,410	(5,989)
Inventory write off	411,431	24,259
Changes in assets and liabilities:
Trade accounts and other receivables	182,533	(344,449)
Advances to suppliers	1,845	294,625
Inventories	719,121	(791,042)
Trade accounts payable	(821,907)	(238,684)
Other payables and accrued expenses	(241,434)	(425,153)
Advances from customers	11,142	(458,999)
Prepaid expenses	(6,053)	(44,936)
Net Cash Used in Operating Activities	(657,884)	(1,684,649)
Cash Flows from Investing Activity:
Purchases of property and equipment	(28,086)	60,465
Net Cash (used in) provided by Investing Activity	(28,086)	60,465
Cash Flows from Financing Activities:
Payments of line of credit	(492,761)
Proceeds from lines of credit	492,761	505,114
Borrowings and interest from related party	13,708	14,057
Net Cash Provided By Financing Activities	13,708	519,171
Effect of Exchange Rate Changes on Cash	(12,239)	(23,048)
Net Decrease in Cash, Cash Equivalents and Restricted Cash	(684,501)	(1,128,061)
Cash and Cash Equivalents at Beginning of Period	1,423,838	2,029,971
Cash, Cash Equivalents and Restricted Cash at End of Period	739,337	901,910
Supplemental Cash Flow Information:
Cash paid for income taxes
Cash paid for interest	43,217	39,681
Supplemental Noncash Investing and Financing Activities:
Accounts receivable collected with banker’s acceptances	187,111	421,458
Inventory purchased with banker’s acceptances	237,336	351,463
Conversions of Note Payable to common stock	1,050,000	800,000
Issuances of stock for intangible assets	1,365,000
Lease liabilities arising from obtaining right-of-use assets		$ 158,926

Organization and Significant Ac

Organization and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Organization and Significant Accounting Policies [Abstract]
ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES Organization and Nature of Operations – Onny acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson’s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing its Wholly Foreign Owned Enterprise (“WFOE”) status on June 21, 2005. Helpson is principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. All of its operations are conducted in the PRC, where its manufacturing facilities are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the “NMPA”, formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy. Liquidity and Going Concern As of June 30, 2024, the Company had cash and cash equivalents of $0.7 million, an accumulated deficit of $41.7 million and the Company’s current liabilities exceeded current assets by $0.7 million. In addition, the Company had incurred net losses of $2.4 million and had negative cash flows from operating activities of $0.7 million for the six months ended June 30, 2024. The Company’s Chairperson, Chief Executive Officer and Interim Chief Financial Officer had advanced an aggregate of $1,140,775 as of June 30, 2024 to provide working capital and enabled the Company to make the required payments related to its former construction loan facility. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its existing products, debt service costs and selling and administrative costs. These conditions raise substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, management plans to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company’s existing property, plant and equipment can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising substantial doubt about its ability to continue as a going concern. Pursuant to the requirements of Accounting Standards Codification (ASC) 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Under ASC 205-40, the strategic alternatives being pursued by the Company cannot be considered probable at this time because none of the Company’s current plans have been finalized at the time of the issuance of these financial statements and the implementation of any such plan is not probable of being effectively implemented as none of the plans are entirely within the Company’s control. Accordingly, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. Reverse Stock Split Consolidation and Basis of Presentation Helpson’s functional currency is the Chinese Renminbi. Helpson’s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson’s financial statements are included in accumulated other comprehensive income, which is a component of stockholders’ equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. All significant intercompany transactions and balances are eliminated on consolidation. However, the results of operations included in such financial statements may not necessary be indicative of annual results. Such financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024 (“2023 Annual Report”). Accounting Estimates The Company uses the same accounting policies in preparing its quarterly and annual financial statements. Certain information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Loss Per Share The potentially dilutive common shares related to the convertible, redeemable note payable of 2,003,001 and 2,155,964 at June 30, 2024 and December 31, 2023 as discussed in Note 9, respectively, and the option to purchase 13,300 shares of common stock at June 30, 2024 and December 31, 2023 are excluded from the computation of diluted net loss per share for all periods presented because the effect is anti-dilutive due to net losses of the Company. Recent Accounting Pronouncements In December 2023, the FASB issued guidance to enhance transparency of income tax disclosures. On an annual basis, the new guidance requires a public entity to disclose: (1) specific categories in the rate reconciliation, (2) additional information for reconciling items that are equal to or greater than 5% of the amount computed by multiplying income (or loss) from continuing operations before income tax expense (or benefit) by the applicable statutory income tax rate, (3) income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes, with foreign taxes disaggregated by individual jurisdictions in which income taxes paid is equal to or greater than 5% of total income taxes paid, (4) income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign, and (5) income tax expense (or benefit) from continuing operations disaggregated between federal (national), state and foreign. The guidance is effective for fiscal year 2025 annual reporting, with early adoption permitted, to be applied on a prospective basis, with retrospective application permitted. We do not expect the adoption of this accounting standard to have an impact on our Consolidated Financial Statements but will require certain additional disclosures. From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of ASUs. Unless otherwise discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on its consolidated financial statements upon adoption.

Accounts Receivable, Net

Accounts Receivable, Net	6 Months Ended
	Jun. 30, 2024
Accounts Receivable, Net [Abstract]
ACCOUNTS RECEIVABLE, NET	NOTE 2 – ACCOUNTS RECEIVABLE, NET Accounts receivable, net, consist of the following: June 30, December 31, 2024 2023 Trade accounts receivable 13,960,927 14,290,522 Less: allowance for doubtful accounts (13,706,077 ) (13,786,074 ) Trade accounts receivable, net $ 254,850 $ 504,448 We recognize bad debt expenses per actual write-offs as well as changes of allowance for doubtful accounts. To the extent that our current allowance for doubtful accounts is higher than that of the previous period, we recognize a bad debt expense for the difference during the current period, and when the current allowance is lower than that of the previous period, we recognize a bad debt credit for the difference. The allowance for doubtful account balances were $13.71 million and $13.79 million as of June 30, 2024 and December 31, 2023, respectively. The changes in the allowances for doubtful accounts during the three and six months ended June 30, 2024 and 2023 were as follows: For the Three Months Ended For the Six Months Ended June 30, June 30, 2024 2023 2024 2023 Balance, Beginning of Period 13,759,993 16,955,959 13,786,074 16,739,527 Bad debt expense (reversal of allowance for doubtful accounts) 8,476 4,047 6,410 (5,989 ) Foreign currency translation adjustment (62,392 ) (834,751 ) (86,407 ) (608,283 ) Balance, End of Period 13,706,077 16,125,255 13,706,077 16,125,255

Inventories

Inventories	6 Months Ended
	Jun. 30, 2024
Inventories [Abstract]
INVENTORIES	NOTE 3 – INVENTORIES Inventories consisted of the following: June 30, December 31, 2024 2023 Raw materials 1,194,063 1,849,213 Work in process 87,308 413,597 Finished goods 1,537,554 1,469,707 Total Inventories $ 2,818,925 $ 3,732,517

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 4 – PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment consisted of the following: June 30, December 31, 2024 2023 Permit of land use $ 395,223 $ 397,684 Building 9,177,692 9,234,836 Plant, machinery and equipment 27,029,997 27,170,123 Motor vehicle 301,818 303,697 Office equipment 386,334 388,740 Total 37,291,064 37,495,080 Less: accumulated depreciation (31,473,685 ) (30,394,655 ) Property, plant and equipment, net $ 5,817,379 $ 7,100,425 Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows: Asset Life – years Permit of land use 40 – 70 Building 20 – 49 Plant, machinery and equipment 5 – 10 Motor vehicle 5 – 10 Office equipment 3-5 Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue. Depreciation expense was $636,721 and $640,979 for the three months ended June 30, 2024 and 2023, respectively and $1,270,981 and $1,265,700 for the six months ended June 30, 2024, respectively .

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2024
Intangible Assets [Abstract]
INTANGIBLE ASSETS	NOTE 5 – INTANGIBLE ASSETS Intangible assets represent the cost of medical formulas approved for production by the NMPA, the intellectual property acquired (“Bonier Agreement”) from Chengdu Bonier Medical Technology Development Co., Ltd. (“Bonier”), the Technology Transfer Agreement with Tao Liu, and the Technology Transfer Agreement with Lihua Li, both are discussed below. No costs were reclassified from advances to intangible assets during the six months ended June 30, 2024 and 2023, respectively. Approved medical formulas are amortized from the date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years. It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets was $104,922 and $55,161 for the three months ended June 30, 2024 and $202,069 and $109,024 for the six months ended June 30, 2024 and 2023, respectively, which was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of their amortization period. On February 2, 2024, Helpson entered into a Technology Transfer Agreement (the “Lihua Li Agreement”) with Lihua Li (“Transferor Li”). Transferor Li owns an invention patent of a pharmaceutical composition for treatment of psoriasis (the “Li Invention Patent”). Pursuant to the Lihua Li Agreement, Transferor Li will transfer the ownership of the Li Invention Patent to Helpson. Transferor Li or his designated third party shall provide relevant technical services in Haikou, which include but are not limited to product research and development, writing of registration materials, registration application. The aggregate transfer price as contemplated by the Agreement is $1.365 million which was paid to the Transferor and his two designees upon the issuance of 3,000,000 shares of common stock of the Company at $0.455 per share based on the closing market price of the Company’s common stock as of the closing date. The Company recorded the amount as intangible assets on the accompanying balance sheet as of the closing date. The value of the intangible asset will be amortized over its remaining useful life of approximately 20 years. During the ten years after the product launches to the market, if and only if the product generates profit, Helpson shall pay 10% of the net profit of the sales in cash on an annual basis to Transferor Li. On December 15, 2023, the Company entered into a Technology Transfer Agreement (the “Tao Liu Agreement”) with Tao Liu (“Transferor Liu”). Transferor Liu owns an invention patent of a drug combination for the treatment of chronic obstructive pulmonary disease (the “Liu Invention Patent”). Pursuant to the Tao Liu Agreement, Transferor Liu will transfer the ownership of the Liu Invention Patent to Helpson. Transferor Liu or his designated third party shall provide relevant technical services in Haikou, which include but are not limited to product research and development, writing of registration materials, registration application and other technical services. During the ten years after the product launches to the market, if and only if the product generates profit, Helpson shall pay 15% of the net profit of the sales in cash on an annual basis to Transferor Liu. On November 28, 2022, the Company entered into a Technology Transfer Contract with Bonier. Bonier owns the know-how of a technical invention and creation of an ophthalmic oxygen enriched atomization therapeutic instrument, which has obtained a utility model patent (the “Utility Model Patent”) and applied for an invention patent (the “Bonier Invention Patent”) at the same time. Pursuant to the Bonier Agreement, Bonier will transfer the ownership of the Utility Model Patent of the technical invention and the Bonier Invention Patent application right of the invention to Helpson. Bonier or its designated third party shall provide relevant technical services in Haikou, which include but are not limited to product research and development, writing of registration materials, registration application and other technical services, with a term of ten years. The Company will pay a service fee of 15% of the net profit of the corresponding product sales revenue, which will be paid in cash annually after it launches to the market, contingent on the successful authorization of the above mentioned Bonier Invention Patent. There were no service fees or profit payments paid related to the above three agreements for the three and six months ended June 30, 2024 and 2023, respectively. The Company evaluates each approved medical formula for impairment at the date of NMPA approval, when indications of impairment are present and also at the date of each financial statement. The Company’s evaluation is based on an estimated undiscounted net cash flow model, which considers currently available market data for the related drug and the Company’s estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. No impairment loss was recognized during the three and six months ended June 30, 2024 and 2023. Intangible assets consisted of NMPA approved medical formulas, a Utility Model Patent and two Invention Patents as follows: June 30, December 31, 2024 2023 NMPA approved medical formulas $ 4,736,859 $ 4,766,353 Technology from Bonier 1,715,813 1,726,497 Invention Patents 3,002,782 1,653,028 9,455,454 8,145,878 Accumulated amortization (5,061,837 ) (4,890,646 ) Net carrying amount $ 4,393,617 $ 3,255,232

Other Payables

Other Payables	6 Months Ended
	Jun. 30, 2024
Other Payables [Abstract]
OTHER PAYABLES	NOTE 6 – OTHER PAYABLES Other Payables consisted of the following: June 30, December 31, 2024 2023 Compensation payable to officer $ 1,251,506 $ 1,243,506 Compensation and interest to related parties 20,000 12,000 Business taxes and other 335,485 1,027,186 Total Other Payables $ 1,606,991 $ 2,282,692

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 7 – RELATED PARTY TRANSACTIONS The Company had previously received advances from its Chairperson Li. Total amounts owed were $1,140,775 and $1,133,809 and are recorded as “Borrowings from related parties” on the accompanying condensed consolidated balance sheets as of June 30, 2024 and December 31, 2023, respectively. On July 8, 2019 the Company entered into a loan agreement in exchange for cash of RMB 4,770,000 ($738,379) with its Chairperson Li. The loan bears interest at a rate of 4.35% and was payable within one year of the loan agreement. The due date of the loan agreement has been extended annually on identical terms, and is due July 9, 2024. Total interest expense related to the loan for the three months ended June 30, 2024 and 2023 was $6,852 and $6,945, respectively and $13,708 and $14,057 for the six months ended June 30, 2024 and 2023, respectively. Compensation payable to the Chairperson Li is included in “Other payables” in the accompanying condensed consolidated balance sheet totaling $1,251,506 and $1,243,506 as of June 30, 2024 and December 31, 2023, respectively.

Lines of Credit

Lines of Credit	6 Months Ended
	Jun. 30, 2024
Lines of Credit [Abstract]
LINES OF CREDIT	NOTE 8 – LINES OF CREDIT On December 21, 2022 the Company entered into a new line of credit for an aggregate amount of RMB 7,300,000 (approximately $1.0 million) with interest payable monthly at a rate of 3.9% with Bank of Communications. The Company received an advance on the line of credit in the amount of RMB 3,800,000 (approximately $0.56 million) on December 30, 2022. On February 24, 2023 the Company received an advance on the line in the amount of RMB 3,500,000 (approximately $0.51 million). The Company has no further availability on this line of credit. The line of credit was paid in full on December 15, 2023, five days before the due date of December 20, 2023. On December 20, 2023, the Company received a new line of credit in the amount of RMB 3,800,000 and an interest rate of 3.9% and is due December 15, 2024. In addition, the Company’s Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit and pledged personal assets as collateral for the loan. Total interest expense under this facility for the three months ended June 30, 2024 and 2023 was $10,237 and $5,465, respectively and $19,302 and $10,568. On February 2, 2024 the Company repaid RMB 3,500,000 under this line of credit. On February 22, 2024 the Company entered into a new agreement on identical terms and received an advance on the line in the amount of RMB 3,500,000 which is due of February 20, 2025 On September 30, 2022 the Company received a line of credit for RMB 10,000,000 (approximately $1.54 million) with Bank of China. The loan bears interest at the rate of 3.45% and was due September 28, 2023. On September 22, 2023 the Company repaid this note in full. On September 25, 2023 the Company entered into a three-year revolving loan and received proceeds of RMB 10,000,000 (approximately $1.4 million). The interest rate for the loan is 3.35% for the first twelve months of the loan and adjusts based on the latest one-year loan market quotation rate less 10 basis points as published by the China National Interbank Funding Center on the working day prior to each twelve month anniversary of the loan. The loan is due on September 24, 2026. The loan is collateralized by the Company’s new production facility and the included production line equipment and machinery. In addition, the Company’s Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit. Total interest paid on this loan was $11,993 and $12,724 for the three months ended June 30, 2024 and 2023, respectively and $23,915 and $25,320 for the six months ended June 30, 2024 and 2023, respectively. Principal payments required for the remaining terms of the loan facility and lines of credit as of June 30, 2024 are as follows: Year Lines of Credit 2025 1,024,303 2026 1,403,154 $ 2,427,457 Fair Value of Lines of Credit

Convertible Note Payable

Convertible Note Payable	6 Months Ended
	Jun. 30, 2024
Convertible Note Payable [Abstract]
CONVERTIBLE NOTE PAYABLE	NOTE 9 – CONVERTIBLE NOTE PAYABLE On November 17, 2021, China Pharma entered into a Securities Purchase Agreement (the “Agreement”) pursuant to which the Company issued an unsecured convertible promissory note (the “Note”) to an institutional accredited investor Streeterville Capital, LLC (the “Investor”). The transaction contemplated under the Agreement was closed on November 19, 2021. The Note matured on February 17, 2023. On April 13, 2023 China Pharma entered into an Amendment (the “Amendment”) with the Investor which extended the maturity date of the Convertible Note Payable to May 19, 2024. As consideration for the extension, China Pharma agreed to an extension fee of $65,639, representing 2.0% of the balance of the Note and accrued interest on the date of the Amendment. The amount was satisfied by increasing the Note balance by the amount of the extension fee. The Company recorded this as additional interest expense during the second quarter of 2023. In addition, China Pharma decreased the price at which the Investor can convert the balance from 85% to 82% of the lowest daily volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion, and assumed an additional obligation to redeem a portion of the outstanding balance of the Note monthly or be subject to additional penalty fees. On May 23, 2024, the Company entered into an Amendment No. 2 (the “Second Amendment”), to the Note by which the parties have agreed to extend the maturity date of the Note to August 19, 2025. In consideration of the extension, the Company has agreed to pay to the Investor an extension fee equal to two percent (2%) of the outstanding balance of the Note (“Extension Fee”) totaling $10,934, and lower the minimum monthly redemption amount from the outstanding balance of the Note that the Company is obligated to redeem from $150,000 to $37,182.33. The Second Amendment also includes customary representations and warranties by the Company. The Company recognized the Extension Fee as interest expense for the year ending December 31, 2024. The Note was originally convertible into 70,000 shares of China Pharma’s common stock at a price of $75.00 per share through April 19, 2022. Thereafter, the Note was convertible into 35,000 shares at a price of $150.00 per share. As of June 30, 2024 the Note is convertible into 2,736 shares of common stock. Interest accrues on the outstanding balance of the Note at 5% per annum compounded daily. Upon the occurrence of an Event of Default as defined in the Note, interest accrues at the lesser of 22% per annum or the maximum rate permitted by applicable law. In addition, upon any Event of Default, the Investor may accelerate the outstanding balance payable under the Note, which will increase automatically upon such acceleration by 15% or 5%, depending on the nature of the Event of Default. Pursuant to the terms of the Agreement and the Note, the Company must obtain Investor’s consent for certain fundamental transactions such as consolidation, merger with or into another entity (excerpt for a reincorporation merger), disposition of substantial assets, change of control, reorganization or recapitalization. Any occurrence of a fundamental transaction without Investor’s prior written consent will be deemed an Event of Default. Investor may redeem all or any part the outstanding balance of the Note, subject to $500,000 per calendar month, at any time after one hundred twenty-one (121) days from the Purchase Price Date, as defined in the Note, upon three trading days’ notice, in cash or converting into shares of China Pharma’s common stock, at a price equal to 82% multiplied by the lowest daily volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion, subject to certain adjustments and ownership limitations specified in the Note. The Note provides for liquidated damages upon failure to comply with any of the terms or provisions of the Note. The Company may prepay the outstanding balance of the Note with the Investor’s consent. At inception, the Note was redeemable into 176,229 shares based on the lowest volume weighted average price of $29.79085 on the inception date of November 19, 2021. As of June 30, 2024, the Note was redeemable into 2,003,001 shares of common stock based on 82% of the lowest volume weighted average price of $0.2049 on that date. Total interest expense for the three months ended June 30, 2024 and 2023 was $19,058 and $105,545, respectively, and $33,370 and $151,563 for the six months ended June 30, 2024 and 2023, respectively. On January 11, 2024 the Investor delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $0.3945, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 380,228 shares of common stock to the Investor on January 16, 2024. On February 1, 2024 the Investor delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $0.3725, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 402,685 shares of common stock to the Investor on February 5, 2024. On February 16, 2024 the Investor delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $0.3675, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 408,164 shares of common stock to the Investor on February 21, 2024. On April 2, 2024 the Investor discussed in Note 9 delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $0.2927, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 512,470 shares of common stock to the Investor on April 3, 2024. On April 17, 2024 the Investor discussed in Note 9 delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $0.2774, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 540,735 shares of common stock to the Investor on April 19, 2024. On May 20, 2024 the Investor discussed in Note 9 delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $0.2539, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 590,783 shares of common stock to the Investor on May 21, 2024. On June 17, 2024 the Investor discussed in Note 9 delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $0.2137, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 701,918 shares of common stock to the Investor on June 17, 2024.

Leases

Leases	6 Months Ended
	Jun. 30, 2024
Leases [Abstract]
LEASES	NOTE 10 – LEASES The Company has leases for certain office and production facilities in the PRC which are classified as operating leases. The leases contain payment terms for fixed amounts. Options to extend are recognized as part of the lease liabilities and recognized as right of use assets when management estimates to renew the lease. There are no residual value guarantees, no variable lease payments, and no restrictions or covenants imposed by leases. The discount rate used in measuring the lease liabilities and right of use assets was determined by reviewing the Company’s incremental borrowing rate at the initial measurement date. For the , operating lease cost was $19,228 and $17,848, respectively and cash paid for amounts included in the measurement of lease liabilities for operating cash flows from operating leases was $19,947 and $18,744, respectively. For the six months ended June 30, 2024 and 2023, operating lease cost was $38,629 and $37,635, respectively and cash paid for amounts included in the measurement of lease liabilities for operating cash flows from operating leases was $40,074 and $39,525, respectively. Minimum lease payments for the Company’s operating lease liabilities were as follows for the twelve month period ended June 30: 2025 $ 80,148 Total undiscounted cash flows 80,148 Less: Imputed interest (1,520 ) 78,628 Less: Lease liabilities, current portion (78,628 ) Lease liabilities, net of current portion $ - The Company has leases with terms less than one year for certain provincial sales offices that are not material.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2024
Income Taxes [Abstract]
INCOME TAXES	NOTE 11 – INCOME TAXES Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect of a change in tax laws or rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. Liabilities are established for uncertain tax positions expected to be taken in income tax returns when such positions are judged to meet the “more-likely-than-not” threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are included as a component of other expenses. Through December 31, 2023, the Company has not identified any uncertain tax positions that it has taken. U.S. income tax returns for the years ended December 31, 2019 through December 31, 2023 and the Chinese income tax return for the year ended December 31, 2023 are open for possible examination. Under the current tax law in the PRC, the Company is and will be subject to the enterprise income tax rate of 25%. There was no provision for income taxes for the three and six months ended June 30, 2024 and 2023, respectively due to continued net losses of the Company. As of June 30, 2024, Helpson had net operating loss carryforwards for PRC tax purposes of approximately $22.6 million which are available to offset any future taxable income through 2029. Approximately $2.7 million of these carryforwards will expire in December 2024. The Company also has net operating losses for United States federal income tax purposes of approximately $10.3 million of which $5.1 million is available to offset future taxable income, if any, through 2040, and $5.2 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each tax year. U.S. federal tax legislation, commonly referred to as the Tax Cuts and Jobs Act (the “U.S. Tax Reform”), was signed into law on December 22, 2017. The U.S. Tax Reform significantly modified the U.S. Internal Revenue Code by, among other things, reducing the statutory U.S. federal corporate income tax rate from 35% to 21% for taxable years beginning after December 31, 2017; limiting and/or eliminating many business deductions; migrating the U.S. to a territorial tax system with a one-time transition tax on a mandatory deemed repatriation of previously deferred foreign earnings of certain foreign subsidiaries; subject to certain limitations, generally eliminating U.S. corporate income tax on dividends from foreign subsidiaries; and providing for new taxes on certain foreign earnings. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized. Management considers projected future taxable income and tax planning strategies in making this assessment. Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, management believes it is not likely for the Company to realize all benefits of the deferred tax assets as of June 30, 2024 and December 31, 2023. Therefore, the Company provided for a valuation allowance against its deferred tax assets of $21,992,061 and $21,531,017 as of June 30, 2024 and December 31, 2023, respectively. The Company also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2024
Fair Value Measurements [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 12 – FAIR VALUE MEASUREMENTS Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 – Quoted prices in active markets for identical assets or liabilities; Level 2 – Observable inputs other than Level 1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable market data; and Level 3 – Unobservable inputs supported by little or no market activity for financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. The Company uses fair value to measure the value of the banker’s acceptance notes it holds at June 30, 2024 and December 31, 2023. The banker’s acceptance notes are recorded at cost which approximates fair value. The Company held the following assets and liabilities recorded at fair value: Fair Value Measurements at Reporting Date Using Description June 30, Level 1 Level 2 Level 3 Banker’s acceptance notes $ 15,435 $ - $ 15,435 $ - Total $ 15,435 $ - $ 15,435 $ - Fair Value Measurements at Reporting Date Using Description December 31, Level 1 Level 2 Level 3 Banker’s acceptance notes $ 65,915 $ - $ 65,915 $ - Total $ 65,915 $ - $ 65,915 $ -

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2024
Stockholders Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 13 – STOCKHOLDERS’ EQUITY China Pharma is authorized to issue 500,000,000 shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Board of China Pharma. According to relevant PRC laws, companies registered in the PRC, including China Pharma’s PRC subsidiary, Helpson, are required to allocate at least 10% of their after tax income, as determined under the accounting standards and regulations in the PRC, to statutory surplus reserve accounts until the reserve account balances reach 50% of the company’s registered capital prior to their remittance of funds out of the PRC. Allocations to these reserves and funds can only be used for specific purposes and are not transferrable to the parent company in the form of loans, advances or cash dividends. The amount designated for general and statutory capital reserves is $8,145,000 at June 30, 2024 and December 31, 2023. Effective March 6, 2024, the Company implemented a 1-for-5 reverse split of its common stock. The reverse stock split was approved by the Company’s Board of Directors through unanimous written consent and the Company’s stockholders at its Annual Meeting for the fiscal year ended on December 31, 2022, which was held on December 17, 2023. Upon the effectiveness of the reverse stock split, every 5 shares of the Company’s issued and outstanding common stock were automatically converted into one share of issued and outstanding common stock. No fractional shares were issued as a result of the reverse stock split. Instead, any fractional shares that resulted from the split were rounded up to the next whole number. The reverse stock split affects all stockholders uniformly and does not alter any stockholder’s percentage interest in the Company’s outstanding common stock, except for adjustments that may result from the treatment of fractional shares. All share and per share amounts have been retroactively restated for all periods presented in the accompanying unaudited condensed consolidated financial statements. Effective March 6, 2023 implemented a 1-for-10 reverse split of its common stock. The reverse stock split was approved by the Company’s Board of Directors through unanimous written consent and ’s stockholders at its Annual Meeting for the fiscal year ended on December 31, 2021, which was held on December 27, 2022. Upon the effectiveness of the reverse stock split, every 10 shares of ’s issued and outstanding common stock were automatically converted into one share of issued and outstanding common stock. No fractional shares were issued as a result of the reverse stock split. Instead, any fractional shares that resulted from the split were rounded up to the next whole number. The reverse stock split affects all stockholders uniformly and does not alter any stockholder’s percentage interest in ’s outstanding common stock, except for adjustments that may result from the treatment of fractional shares. All share and per share amounts have been retroactively restated for all periods presented in the accompanying unaudited condensed consolidated financial statements. 2024 Share Issuances On January 11, 2024 the Investor delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $0.3945, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 380,228 shares of common stock to the Investor on January 16, 2024. On February 1, 2024 the Investor delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $0.3725, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 402,685 shares of common stock to the Investor on February 5, 2024. On February 16, 2024 the Investor delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $0.3675, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 408,164 shares of common stock to the Investor on February 21, 2024. On April 2, 2024 the Investor discussed in Note 9 delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $0.2927, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 512,470 shares of common stock to the Investor on April 3, 2024. On April 17, 2024 the Investor discussed in Note 9 delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $0.2774, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 540,735 shares of common stock to the Investor on April 19, 2024. On May 20, 2024 the Investor discussed in Note 9 delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $0.2539, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 590,783 shares of common stock to the Investor on May 21, 2024. On June 17, 2024 the Investor discussed in Note 9 delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $0.2137, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 701,918 shares of common stock to the Investor on June 17, 2024. 2010 Incentive Plan On November 12, 2010, the Company’s Board adopted the Company’s 2010 Incentive Plan (the “Plan”), which was then approved by stockholders on December 22, 2010. On October 17, 2019, the Board of Directors approved the First Amendment to the 2010 Incentive Plan (the “Amendment”), pursuant to which the term of the 2010 Incentive Plan was extended to December 31, 2029. The Amendment was adopted by the stockholders on December 19, 2019. On October 25, 2021, the Board of Directors approved, and on December 27, 2021 our stockholders adopted the Amendment No.2 to the Plan to increase the number of shares of the Common Stock, that are reserved thereunder by 100,000 shares from 80,000 shares to 180,000 shares. On October 27, 2022 the Board of Directors approved and on December 27, 2022, the stockholders adopted the Amended and Restated Long Term 2010 Incentive Plan to increase the number of shares of common stock that are reserved thereunder by an additional 100,000 shares from 180,000 to 280,000. On December 17, 2023 the stockholders approved Amendment No. 1 to the Amended and Restated Long Term 2010 Incentive Plan to increase the number of shares from 280,000 to 580,000. The Plan gives the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 580,000 shares of common stock. Through June 30, 2024, there were 84,700 shares of stock and stock options granted and outstanding under the Plan. A total of 13,300 options were outstanding as of June 30, 2024 under the Plan. As such, there are 482,000 additional units available for issuance under the Plan. There were no As of June 30, 2024, there was no remaining unrecognized compensation expense related to stock options or restricted stock grants.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2024
Commitments And Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 14 – COMMITMENTS AND CONTINGENCIES Current vulnerability due to certain concentrations For the six months ended June 30, 2024, no customer accounted for greater than 10.0% of sales and two customers accounted for 63.6% and 13.7% of accounts receivable. Three suppliers accounted for 23.5%, 23.4% and 17.6% of raw material purchases, and three different products accounted for 35.2%, 22.7% and 10.2% of revenue. For the six months ended June 30, 2023, no customer accounted for greater than 10.0% of sales and three customers accounted for 53.4%, 11.5% and 10.5% of accounts receivable. Two suppliers accounted for 19.5% and 18.0% of raw material purchases, and five different products accounted for 22.4%, 19.8%, 11.8%, 10.9% and 10.0% of revenue. Nature of Operations Economic environment - In addition, all of the Company’s revenue is denominated in the PRC’s currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 15 – SUBSEQUENT EVENTS The Company evaluated all events and transactions that occurred after June 30, 2024 up through the date the Company filed these unaudited condensed consolidated financial statements. No events require adjustment to or disclosure in the unaudited condensed consolidated financial statements.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2024
Organization and Significant Accounting Policies [Abstract]
Organization and Nature of Operations	Organization and Nature of Operations – Onny acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson’s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing its Wholly Foreign Owned Enterprise (“WFOE”) status on June 21, 2005. Helpson is principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. All of its operations are conducted in the PRC, where its manufacturing facilities are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the “NMPA”, formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy.
Liquidity and Going Concern	Liquidity and Going Concern As of June 30, 2024, the Company had cash and cash equivalents of $0.7 million, an accumulated deficit of $41.7 million and the Company’s current liabilities exceeded current assets by $0.7 million. In addition, the Company had incurred net losses of $2.4 million and had negative cash flows from operating activities of $0.7 million for the six months ended June 30, 2024. The Company’s Chairperson, Chief Executive Officer and Interim Chief Financial Officer had advanced an aggregate of $1,140,775 as of June 30, 2024 to provide working capital and enabled the Company to make the required payments related to its former construction loan facility. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its existing products, debt service costs and selling and administrative costs. These conditions raise substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, management plans to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company’s existing property, plant and equipment can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising substantial doubt about its ability to continue as a going concern. Pursuant to the requirements of Accounting Standards Codification (ASC) 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Under ASC 205-40, the strategic alternatives being pursued by the Company cannot be considered probable at this time because none of the Company’s current plans have been finalized at the time of the issuance of these financial statements and the implementation of any such plan is not probable of being effectively implemented as none of the plans are entirely within the Company’s control. Accordingly, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.
Reverse Stock Split	Reverse Stock Split
Consolidation and Basis of Presentation	Consolidation and Basis of Presentation Helpson’s functional currency is the Chinese Renminbi. Helpson’s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson’s financial statements are included in accumulated other comprehensive income, which is a component of stockholders’ equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. All significant intercompany transactions and balances are eliminated on consolidation. However, the results of operations included in such financial statements may not necessary be indicative of annual results. Such financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024 (“2023 Annual Report”).
Accounting Estimates	Accounting Estimates The Company uses the same accounting policies in preparing its quarterly and annual financial statements. Certain information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted.
Loss Per Share	Loss Per Share The potentially dilutive common shares related to the convertible, redeemable note payable of 2,003,001 and 2,155,964 at June 30, 2024 and December 31, 2023 as discussed in Note 9, respectively, and the option to purchase 13,300 shares of common stock at June 30, 2024 and December 31, 2023 are excluded from the computation of diluted net loss per share for all periods presented because the effect is anti-dilutive due to net losses of the Company.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2023, the FASB issued guidance to enhance transparency of income tax disclosures. On an annual basis, the new guidance requires a public entity to disclose: (1) specific categories in the rate reconciliation, (2) additional information for reconciling items that are equal to or greater than 5% of the amount computed by multiplying income (or loss) from continuing operations before income tax expense (or benefit) by the applicable statutory income tax rate, (3) income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes, with foreign taxes disaggregated by individual jurisdictions in which income taxes paid is equal to or greater than 5% of total income taxes paid, (4) income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign, and (5) income tax expense (or benefit) from continuing operations disaggregated between federal (national), state and foreign. The guidance is effective for fiscal year 2025 annual reporting, with early adoption permitted, to be applied on a prospective basis, with retrospective application permitted. We do not expect the adoption of this accounting standard to have an impact on our Consolidated Financial Statements but will require certain additional disclosures. From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of ASUs. Unless otherwise discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on its consolidated financial statements upon adoption.

Accounts Receivable, Net (Table

Accounts Receivable, Net (Tables)	6 Months Ended
	Jun. 30, 2024
Accounts Receivable, Net [Abstract]
Schedule of Accounts Receivable, Net	Accounts receivable, net, consist of the following: June 30, December 31, 2024 2023 Trade accounts receivable 13,960,927 14,290,522 Less: allowance for doubtful accounts (13,706,077 ) (13,786,074 ) Trade accounts receivable, net $ 254,850 $ 504,448
Schedule of Changes in the Allowances for Doubtful Accounts	The changes in the allowances for doubtful accounts during the three and six months ended June 30, 2024 and 2023 were as follows: For the Three Months Ended For the Six Months Ended June 30, June 30, 2024 2023 2024 2023 Balance, Beginning of Period 13,759,993 16,955,959 13,786,074 16,739,527 Bad debt expense (reversal of allowance for doubtful accounts) 8,476 4,047 6,410 (5,989 ) Foreign currency translation adjustment (62,392 ) (834,751 ) (86,407 ) (608,283 ) Balance, End of Period 13,706,077 16,125,255 13,706,077 16,125,255

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2024
Inventories [Abstract]
Schedule of Inventories	Inventories consisted of the following: June 30, December 31, 2024 2023 Raw materials 1,194,063 1,849,213 Work in process 87,308 413,597 Finished goods 1,537,554 1,469,707 Total Inventories $ 2,818,925 $ 3,732,517

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment consisted of the following: June 30, December 31, 2024 2023 Permit of land use $ 395,223 $ 397,684 Building 9,177,692 9,234,836 Plant, machinery and equipment 27,029,997 27,170,123 Motor vehicle 301,818 303,697 Office equipment 386,334 388,740 Total 37,291,064 37,495,080 Less: accumulated depreciation (31,473,685 ) (30,394,655 ) Property, plant and equipment, net $ 5,817,379 $ 7,100,425
Schedule of Estimated Useful Lives of the Assets	Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows: Asset Life – years Permit of land use 40 – 70 Building 20 – 49 Plant, machinery and equipment 5 – 10 Motor vehicle 5 – 10 Office equipment 3-5

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2024
Intangible Assets [Abstract]
Schedule of Intangible Assets	Intangible assets consisted of NMPA approved medical formulas, a Utility Model Patent and two Invention Patents as follows: June 30, December 31, 2024 2023 NMPA approved medical formulas $ 4,736,859 $ 4,766,353 Technology from Bonier 1,715,813 1,726,497 Invention Patents 3,002,782 1,653,028 9,455,454 8,145,878 Accumulated amortization (5,061,837 ) (4,890,646 ) Net carrying amount $ 4,393,617 $ 3,255,232

Other Payables (Tables)

Other Payables (Tables)	6 Months Ended
	Jun. 30, 2024
Other Payables [Abstract]
Schedule of Other Payables	Other Payables consisted of the following: June 30, December 31, 2024 2023 Compensation payable to officer $ 1,251,506 $ 1,243,506 Compensation and interest to related parties 20,000 12,000 Business taxes and other 335,485 1,027,186 Total Other Payables $ 1,606,991 $ 2,282,692

Lines of Credit (Tables)

Lines of Credit (Tables)	6 Months Ended
	Jun. 30, 2024
Lines of Credit [Abstract]
Schedule of Principal Payments	Principal payments required for the remaining terms of the loan facility and lines of credit as of June 30, 2024 are as follows: Year Lines of Credit 2025 1,024,303 2026 1,403,154 $ 2,427,457

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2024
Leases [Abstract]
Schedule of Operating Lease Liabilities	Minimum lease payments for the Company’s operating lease liabilities were as follows for the twelve month period ended June 30: 2025 $ 80,148 Total undiscounted cash flows 80,148 Less: Imputed interest (1,520 ) 78,628 Less: Lease liabilities, current portion (78,628 ) Lease liabilities, net of current portion $ -

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2024
Fair Value Measurements [Abstract]
Schedule of Assets and Liabilities Recorded at Fair Value	The Company uses fair value to measure the value of the banker’s acceptance notes it holds at June 30, 2024 and December 31, 2023. The banker’s acceptance notes are recorded at cost which approximates fair value. The Company held the following assets and liabilities recorded at fair value: Fair Value Measurements at Reporting Date Using Description June 30, Level 1 Level 2 Level 3 Banker’s acceptance notes $ 15,435 $ - $ 15,435 $ - Total $ 15,435 $ - $ 15,435 $ - Fair Value Measurements at Reporting Date Using Description December 31, Level 1 Level 2 Level 3 Banker’s acceptance notes $ 65,915 $ - $ 65,915 $ - Total $ 65,915 $ - $ 65,915 $ -

Organization and Significant _2

Organization and Significant Accounting Policies (Details) - USD ($)	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	May 25, 2005
Organization and Significant Accounting Policies [Line Items]
Cash and cash equivalents	$ 700,000				$ 700,000
Accumulated deficit	(41,700,000)				(41,700,000)
Working capital deficit	700,000				700,000
Net losses	(1,438,130)	$ (955,892)	$ (593,029)	$ (475,976)	(2,394,022)	$ (1,069,005)
Cash flows from operating activities					$ (657,884)	$ (1,684,649)
Reverse stock split					1-for -5 reverse stock
Chief Executive Officer and Interim Chief Financial Officer [Member]
Organization and Significant Accounting Policies [Line Items]
Borrowing from related party	$ 1,140,775				$ 1,140,775		$ 1,133,809
Onny Investment Limited [Member]
Organization and Significant Accounting Policies [Line Items]
Ownership percentage	100%				100%
Hainan Helpson Medical & Biotechnology Co., Ltd [Member]
Organization and Significant Accounting Policies [Line Items]
Ownership percentage	100%				100%			100%
Convertible, Redeemable Note Payable [Member]
Organization and Significant Accounting Policies [Line Items]
Potentially dilutive common shares (in Shares)					2,003,001		2,155,964
Options [Member]
Organization and Significant Accounting Policies [Line Items]
Potentially dilutive common shares (in Shares)					13,300		13,300

Accounts Receivable, Net (Detai

Accounts Receivable, Net (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Accounts Receivable, Net [Abstract]
Allowance for doubtful account	$ 13,706,077	$ 13,786,074

Accounts Receivable, Net (Det_2

Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Schedule of Accounts Receivable, Net [Abstract]
Trade accounts receivable	$ 13,960,927	$ 14,290,522
Less: allowance for doubtful accounts	(13,706,077)	(13,786,074)
Trade accounts receivable, net	$ 254,850	$ 504,448

Accounts Receivable, Net (Det_3

Accounts Receivable, Net (Details) - Schedule of Changes in the Allowances for Doubtful Accounts - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Schedule of Changes in the Allowances for Doubtful Accounts [Abstract]
Balance, Beginning of Period	$ 13,759,993	$ 16,955,959	$ 13,786,074	$ 16,739,527
Bad debt expense (reversal of allowance for doubtful accounts)	8,476	4,047	6,410	(5,989)
Foreign currency translation adjustment	(62,392)	(834,751)	(86,407)	(608,283)
Balance, End of Period	$ 13,706,077	$ 16,125,255	$ 13,706,077	$ 16,125,255

Inventories (Details) - Schedul

Inventories (Details) - Schedule of Inventories - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Schedule of Inventories [Abstract]
Raw materials	$ 1,194,063	$ 1,849,213
Work in process	87,308	413,597
Finished goods	1,537,554	1,469,707
Total Inventories	$ 2,818,925	$ 3,732,517

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 636,721	$ 640,979	$ 1,270,981	$ 1,265,700

Property, Plant and Equipment_3

Property, Plant and Equipment (Details) - Schedule of Property, Plant and Equipment - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Schedule of Property, Plant and Equipment [Line Items]
Total	$ 37,291,064	$ 37,495,080
Less: accumulated depreciation	(31,473,685)	(30,394,655)
Property, plant and equipment, net	5,817,379	7,100,425
Permit of land use [Member]
Schedule of Property, Plant and Equipment [Line Items]
Total	395,223	397,684
Building [Member]
Schedule of Property, Plant and Equipment [Line Items]
Total	9,177,692	9,234,836
Plant, machinery and equipment [Member]
Schedule of Property, Plant and Equipment [Line Items]
Total	27,029,997	27,170,123
Motor vehicles [Member]
Schedule of Property, Plant and Equipment [Line Items]
Total	301,818	303,697
Office equipment [Member]
Schedule of Property, Plant and Equipment [Line Items]
Total	$ 386,334	$ 388,740

Property, Plant and Equipment_4

Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of the Assets	Jun. 30, 2024
Minimum [Member] | Permit of land use [Member]
Schedule of Estimated Useful Lives of the Assets [Line Items]
Estimated useful lives	40 years
Minimum [Member] | Building [Member]
Schedule of Estimated Useful Lives of the Assets [Line Items]
Estimated useful lives	20 years
Minimum [Member] | Plant, machinery and equipment [Member]
Schedule of Estimated Useful Lives of the Assets [Line Items]
Estimated useful lives	5 years
Minimum [Member] | Motor vehicle [Member]
Schedule of Estimated Useful Lives of the Assets [Line Items]
Estimated useful lives	5 years
Minimum [Member] | Office equipment [Member]
Schedule of Estimated Useful Lives of the Assets [Line Items]
Estimated useful lives	3 years
Maximum [Member] | Permit of land use [Member]
Schedule of Estimated Useful Lives of the Assets [Line Items]
Estimated useful lives	70 years
Maximum [Member] | Building [Member]
Schedule of Estimated Useful Lives of the Assets [Line Items]
Estimated useful lives	49 years
Maximum [Member] | Plant, machinery and equipment [Member]
Schedule of Estimated Useful Lives of the Assets [Line Items]
Estimated useful lives	10 years
Maximum [Member] | Motor vehicle [Member]
Schedule of Estimated Useful Lives of the Assets [Line Items]
Estimated useful lives	10 years
Maximum [Member] | Office equipment [Member]
Schedule of Estimated Useful Lives of the Assets [Line Items]
Estimated useful lives	5 years

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Intangible Assets [Line Items]
Amortization intangible by useful life, descriptions			Approved medical formulas are amortized from the date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years.
Amortization expense relating to intangible assets	$ 104,922	$ 55,161	$ 202,069	$ 109,024
Transfer price			$ 1,365,000
Issuance of common stock (in Shares)			3,000,000
Price per share (in Dollars per share)	$ 0.455		$ 0.455
Intangible asset useful life term	20 years		20 years
Net profit sales rate	10%		10%
Percentage of net profit			15%
Helpson [Member]
Intangible Assets [Line Items]
Percentage of net profit			15%

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of Intangible Assets - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Schedule of Intangible Assets [Line Items]
Gross carrying amount	$ 9,455,454	$ 8,145,878
Accumulated amortization	(5,061,837)	(4,890,646)
Net carrying amount	4,393,617	3,255,232
NMPA approved medical formulas [Member]
Schedule of Intangible Assets [Line Items]
Gross carrying amount	4,736,859	4,766,353
Technology from Bonier [Member]
Schedule of Intangible Assets [Line Items]
Gross carrying amount	1,715,813	1,726,497
Invention Patents [Member]
Schedule of Intangible Assets [Line Items]
Gross carrying amount	$ 3,002,782	$ 1,653,028

Other Payables (Details) - Sche

Other Payables (Details) - Schedule of Other Payables - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Schedule of Other Payables [Abstract]
Compensation payable to officer	$ 1,251,506	$ 1,243,506
Compensation and interest to related parties	20,000	12,000
Business taxes and other	335,485	1,027,186
Total Other Payables	$ 1,606,991	$ 2,282,692

Related Party Transactions (Det

Related Party Transactions (Details)			3 Months Ended		6 Months Ended
	Jul. 08, 2019 USD ($)	Jul. 08, 2019 CNY (¥)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Related Party Transactions [Line Items]
Loan payment	$ 738,379	¥ 4,770,000
Term of loan agreement			1 year		1 year
Interest expense			$ 6,852	$ 6,945	$ 13,708	$ 14,057
Chairperson [Member]
Related Party Transactions [Line Items]
Borrowings from related parties			1,140,775		1,140,775		$ 1,133,809
Other payables			$ 1,251,506		$ 1,251,506		$ 1,243,506
Loan Payable [Member]
Related Party Transactions [Line Items]
Interest rate	4.35%	4.35%

Lines of Credit (Details)

Lines of Credit (Details)

3 Months Ended

6 Months Ended

Feb. 22, 2024 USD ($)

Feb. 02, 2024 CNY (¥)

Dec. 20, 2023 CNY (¥)

Feb. 24, 2023 USD ($)

Feb. 24, 2023 CNY (¥)

Dec. 30, 2022 USD ($)

Dec. 30, 2022 CNY (¥)

Dec. 21, 2022 USD ($)

Sep. 30, 2022 USD ($)

Sep. 25, 2022 USD ($)

Sep. 25, 2022 CNY (¥)

Jun. 30, 2024 USD ($)

Jun. 30, 2023 USD ($)

Jun. 30, 2024 USD ($)

Jun. 30, 2023 USD ($)

Dec. 21, 2022 CNY (¥)

Sep. 30, 2022 CNY (¥)

Bank of Communications [Member]

Line of Credit [Line Items]

Line of credit facility amount

$ 1,000,000

¥ 7,300,000

Interest rate of line of credit

3.90%

3.90%

Line of credit received in advance

$ 3,500,000

¥ 3,800,000

$ 510,000

¥ 3,500,000

$ 560,000

¥ 3,800,000

Due date of line of credit

Feb. 20, 2025

Dec. 15, 2024

Interest expenses

$ 10,237

$ 5,465

$ 19,302

$ 10,568

Repayments of line of credit (in Yuan Renminbi) | ¥

¥ 3,500,000

Bank of China [Member]

Line of Credit [Line Items]

Line of credit facility amount | ¥

¥ 10,000,000

Interest rate of line of credit

3.45%

3.35%

3.35%

Due date of line of credit

Sep. 28, 2023

Sep. 24, 2026

Sep. 24, 2026

Line of credit facility borrowing amount

$ 1,540,000

Interest paid

$ 11,993

$ 12,724

$ 23,915

$ 25,320

Bank of China [Member] | Revolving Credit Facility [Member]

Line of Credit [Line Items]

Received proceeds from loan

$ 1,400,000

¥ 10,000,000

Lines of Credit (Details) - Sch

Lines of Credit (Details) - Schedule of Principal Payments - Lines of Credit [Member]	Jun. 30, 2024 USD ($)
Line of Credit Facility [Line Items]
2025	$ 1,024,303
2026	1,403,154
Total	$ 2,427,457

Convertible Note Payable (Detai

Convertible Note Payable (Details)																		3 Months Ended		6 Months Ended
	Jun. 17, 2024 USD ($) $ / shares shares	May 23, 2024 USD ($)	May 21, 2024 shares	May 20, 2024 USD ($) $ / shares	Apr. 19, 2024 shares	Apr. 17, 2024 USD ($) $ / shares	Apr. 03, 2024 shares	Apr. 02, 2024 USD ($) $ / shares	Feb. 21, 2024 shares	Feb. 16, 2024 USD ($) $ / shares	Feb. 05, 2024 shares	Feb. 01, 2024 USD ($) $ / shares	Jan. 16, 2024 shares	Jan. 11, 2024 USD ($) $ / shares	Apr. 13, 2023 USD ($)	Apr. 19, 2022 $ / shares	Nov. 19, 2021 $ / shares	Jun. 30, 2024 USD ($) $ / shares	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($)
Convertible Note Payable [line Items]
Debt extension fee (in Dollars)															$ 65,639
Note and accrued interest															2%
Debt redemptions weighted average price																				82%
Number of trading days	10 days			10 days		10 days		10 days		10 days		10 days		10 days	10 days			10 days		10 days
Extension fee		2%
Outstanding balance of extension fee (in Dollars)		$ 10,934
Description of interest accrued																				Interest accrues on the outstanding balance of the Note at 5% per annum compounded daily. Upon the occurrence of an Event of Default as defined in the Note, interest accrues at the lesser of 22% per annum or the maximum rate permitted by applicable law. In addition, upon any Event of Default, the Investor may accelerate the outstanding balance payable under the Note, which will increase automatically upon such acceleration by 15% or 5%, depending on the nature of the Event of Default.
Redeem of outstanding note (in Dollars)																				$ 500,000
Debt instrument redemption price percentage	82%			82%		82%		82%		82%		82%		82%
Note redeemable into shares (in Shares) | shares																				2,003,001
Weighted average price (in Dollars per share) | $ / shares																				$ 0.2049
Debt redemption amount (in Dollars)	$ 150,000			$ 150,000		$ 150,000		$ 150,000		$ 150,000		$ 150,000		$ 150,000
Stock issued during period shares (in Shares) | shares	701,918		590,783		540,735		512,470		408,164		402,685		380,228
Convertible Notes [Member]
Convertible Note Payable [line Items]
Note converted into common stock																70,000	176,229			2,736
Conversion price (in Dollars per share) | $ / shares	$ 0.2137			$ 0.2539		$ 0.2774		$ 0.2927		$ 0.3675		$ 0.3725		$ 0.3945			$ 29.79085	$ 150		$ 150
Debt instrument redemption price percentage																				82%
Interest expense (in Dollars)																		$ 19,058	$ 105,545	$ 33,370	$ 151,563
Debt redemption amount (in Dollars)														$ 150,000
Convertible Notes [Member] | China Pharma’s [Member]
Convertible Note Payable [line Items]
Note converted into common stock																				35,000
Minimum [Member]
Convertible Note Payable [line Items]
Debt redemptions weighted average price															85%
Redemption amount (in Dollars)		150,000
Maximum [Member]
Convertible Note Payable [line Items]
Debt redemptions weighted average price															82%
Redemption amount (in Dollars)		$ 37,182.33
Common Stock [Member] | Convertible Notes [Member] | China Pharma’s [Member]
Convertible Note Payable [line Items]
Conversion price (in Dollars per share) | $ / shares																$ 75

Leases (Details)

Leases (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Leases [Abstract]
Operating lease cost	$ 19,228	$ 17,848	$ 38,629	$ 37,635
Operating lease payments	19,947	$ 18,744	40,074	$ 39,525
Operating lease right of use assets	77,259		77,259		$ 116,610
Operating liability	$ 78,628		$ 78,628		$ 117,637
Operating lease weighted average lease term	1 year		1 year
Operating lease weighted average discount rate	3.55%		3.55%

Leases (Details) - Schedule of

Leases (Details) - Schedule of Operating Lease Liabilities - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Schedule of Operating Lease Liabilities [Abstract]
2025	$ 80,148
Total undiscounted cash flows	80,148
Less: Imputed interest	(1,520)
Total	78,628	$ 117,637
Less: Lease liabilities, current portion	(78,628)	(77,727)
Lease liabilities, net of current portion		$ 39,910

Income Taxes (Details)

Income Taxes (Details) - USD ($)		6 Months Ended
	Dec. 31, 2017	Jun. 30, 2024	Dec. 31, 2023
Income Taxes [Line Items]
Enterprise income tax rate		25%
Operating loss carryforwards		$ 22,600,000
Operating loss carryforwards limitations, descriptions		through 2040, and $5.2 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each tax year
Valuation allowance on deferred tax assets		$ 21,992,061	$ 21,531,017
Maximum [Member]
Income Taxes [Line Items]
U.S. federal corporate income tax rate	35%
Minimum [Member]
Income Taxes [Line Items]
U.S. federal corporate income tax rate	21%
Domestic Tax Jurisdiction [Member]
Income Taxes [Line Items]
Operating loss carryforwards		10,300,000
Operating loss carryforwards available for future taxable income		5,100,000
Tax Year 2023 [Member]
Income Taxes [Line Items]
Operating loss carryforwards		$ 2,700,000

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Schedule of Assets and Liabilities Recorded at Fair Value - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]
Total	$ 15,435	$ 65,915
Level 1 [Member]
Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]
Total
Level 2 [Member]
Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]
Total	15,435	65,915
Level 3 [Member]
Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]
Total
Banker's Acceptance Notes [Member]
Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]
Total	15,435	65,915
Banker's Acceptance Notes [Member] | Level 1 [Member]
Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]
Total
Banker's Acceptance Notes [Member] | Level 2 [Member]
Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]
Total	15,435	65,915
Banker's Acceptance Notes [Member] | Level 3 [Member]
Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]
Total

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)														6 Months Ended
	Jun. 17, 2024	May 21, 2024	May 20, 2024	Apr. 19, 2024	Apr. 17, 2024	Apr. 03, 2024	Apr. 02, 2024	Feb. 21, 2024	Feb. 16, 2024	Feb. 05, 2024	Feb. 01, 2024	Jan. 16, 2024	Jan. 11, 2024	Jun. 30, 2024	Dec. 31, 2023	Dec. 17, 2023	Apr. 13, 2023	Dec. 27, 2022	Dec. 27, 2021	Nov. 19, 2021
Stockholders Equity [Line Items]
Common stock, shares authorized														500,000,000	500,000,000
Common stock, par value (in Dollars per share)														$ 0.001	$ 0.001
Preferred stock, shares authorized														5,000,000	5,000,000
Preferred stock, par value (in Dollars per share)														$ 0.001	$ 0.001
After tax income, percentage														10%
Reserve account balances, percentage														50%
General and statutory capital reserves amount (in Dollars)														$ 8,145,000	$ 8,145,000
Common stock shares issued														17,162,771	10,625,788
Common stock shares outstanding														17,162,771	10,625,788
Reverse stock split, description														1-for -5 reverse stock
Redemption amount (in Dollars)	$ 150,000		$ 150,000		$ 150,000		$ 150,000		$ 150,000		$ 150,000		$ 150,000
Lowest volume weighted average price	82%		82%		82%		82%		82%		82%		82%
Number of trading days	10 days		10 days		10 days		10 days		10 days		10 days		10 days	10 days			10 days
Issued shares	701,918	590,783		540,735		512,470		408,164		402,685		380,228
Common stock reserved shares																		100,000	100,000
Total option outstanding														13,300
Additional shares available for issuance														482,000
Issuance of securities (in Dollars)
Compensation expense (in Dollars)														0
Unrecognized compensation expense (in Dollars)														$ 0
Convertible Notes [Member]
Stockholders Equity [Line Items]
Redemption amount (in Dollars)													$ 150,000
Conversion price (in Dollars per share)	$ 0.2137		$ 0.2539		$ 0.2774		$ 0.2927		$ 0.3675		$ 0.3725		$ 0.3945	$ 150						$ 29.79085
Lowest volume weighted average price														82%
Minimum [Member]
Stockholders Equity [Line Items]
Common stock reserved shares																280,000		180,000	80,000
Maximum [Member]
Stockholders Equity [Line Items]
Common stock reserved shares																580,000		280,000	180,000
China Pharma’s Common Stock [Member]
Stockholders Equity [Line Items]
Common stock shares issued														10
Common stock shares outstanding														10
China Pharma’s Common Stock [Member] | Convertible Notes [Member]
Stockholders Equity [Line Items]
Common stock shares issued														1
Common stock shares outstanding														1
Two Thousand Ten Incentive Plan [Member]
Stockholders Equity [Line Items]
Common stock shares issued														84,700
Common stock shares outstanding														84,700
Common stock issued														580,000
Common Stock [Member]
Stockholders Equity [Line Items]
Common stock shares issued														5
Common stock shares outstanding														5
Converted share issued and outstanding														1
Reverse stock split, description														1-for-10

Commitments and Contingencies (

Commitments and Contingencies (Details)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Customer Concentration Risk [Member] | Customer One [Member] | Accounts Receivable [Member]
Commitments And Contingencies [Line Items]
Concentration risk percentage	63.60%	53.40%
Customer Concentration Risk [Member] | Customer Two [Member] | Accounts Receivable [Member]
Commitments And Contingencies [Line Items]
Concentration risk percentage	13.70%	11.50%
Customer Concentration Risk [Member] | Customer Three [Member] | Accounts Receivable [Member]
Commitments And Contingencies [Line Items]
Concentration risk percentage		10.50%
Supplier Concentration Risk [Member] | Accounts Payable [Member] | Suppliers One [Member]
Commitments And Contingencies [Line Items]
Concentration risk percentage	23.50%
Supplier Concentration Risk [Member] | Accounts Payable [Member] | Suppliers Two [Member]
Commitments And Contingencies [Line Items]
Concentration risk percentage	23.40%
Supplier Concentration Risk [Member] | Accounts Payable [Member] | Suppliers Three [Member]
Commitments And Contingencies [Line Items]
Concentration risk percentage	17.60%
Supplier Concentration Risk [Member] | Raw Material Purchases [Member] | Suppliers One [Member]
Commitments And Contingencies [Line Items]
Concentration risk percentage		19.50%
Supplier Concentration Risk [Member] | Raw Material Purchases [Member] | Suppliers Two [Member]
Commitments And Contingencies [Line Items]
Concentration risk percentage		18%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Product One [Member]
Commitments And Contingencies [Line Items]
Concentration risk percentage	35.20%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Product Two [Member]
Commitments And Contingencies [Line Items]
Concentration risk percentage	22.70%	19.80%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Product Three [Member]
Commitments And Contingencies [Line Items]
Concentration risk percentage	10.20%	11.80%
Product Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member] | Product One [Member]
Commitments And Contingencies [Line Items]
Concentration risk percentage		22.40%
Product Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member] | Product Four [Member]
Commitments And Contingencies [Line Items]
Concentration risk percentage		10.90%
Product Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member] | Product Five [Member]
Commitments And Contingencies [Line Items]
Concentration risk percentage		10%